Trial | NCT01338103  Report issue

Title

Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex
Treatment of Moderate to Severe Patients With Pemphigus With the Monoclonal Anti CD20 Antibody Rituximab at a Protocol of 1000mgX2 and Assessment of Their Immune Status Via the Cylex Test

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    rituximab ...

  • Study Participants

    10
The purpose of this study is to determine whether Rituximab, in the same doses as used in rheumatoid arthritis patients, will benefit pemphigus patients. It also tests immune function via the Cylex assay in pemphigus patients before and after treatment with RItuximab.
Study Started
Jan 31
2010
Primary Completion
Jun 30
2012
Anticipated
Study Completion
Jun 30
2012
Anticipated
Last Update
May 02
2011
Estimate

Drug Rituximab

intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.

Rituximab Experimental

Criteria 

Inclusion Criteria:

1. Pemphigus patients with moderate-severe disease

Exclusion Criteria:

Pregnancy or lactation
Woman of reproductive age not using birth control measures.
Prior severe allergy or anaphylaxis with a human monoclonal antibody
Heart failure
Unstable angina or ischemic heart disease
Uncontrolled arrhythmia
HIV positive
Active hepatitis B infection or positive for hepatitis C virus (HCV) antibodies.
Severe dementia or a psychiatric illness
Active acute infection
No Results Posted